Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Lenvatinib + Pembrolizumab - Endometrial Cancer, the FDA granted accelerated approval on 17 September 2019 for Lenvatinib + Pembrolizumab in patients with advanced endometrial carcinoma that is not MSI‑H or dMMR, after prior systemic therapy and when curative surgery or radiotherapy are not options (1, 2). Subsequent phase III data (KEYNOTE‑775/Study 309) confirmed benefit versus physician’s‑choice chemotherapy, supporting this regimen as a standard second‑line option irrespective of MMR status (3, 4).
European and international reviews describe pembrolizumab + lenvatinib as an established systemic …